General Anesthesia Drugs Market Size, Share, Growth Analysis, By Drug Type (Propofol, Sevoflurane), By Route of Administration (Intravenous, Inhaled), By End-Use (Hospitals, Ambulatory Surgical Centers), By Application, By Region - Industry Forecast 2025-2032

North America currently dominates the anaesthetic drugs industry and is anticipated to maintain its dominance over the forecast year. The United States has the world's largest regional market. With the introduction of COVID-19, the United States experienced severe shortages of critical anaesthetic medicines, including midazolam, dexmedetomidine, propofol, and neuromuscular blocking agents. As a result, numerous corporations are increasing their anaesthetic medication manufacturing. For instance, Hikma Pharmaceutical introduced a brand-new medicine, "Propofol Injectable Emulsion," in the United States. Furthermore, this market is being pushed by an increase in the number of operations, an ageing population with an increase in chronic illnesses, and developments in anaesthetic technology.

According to the American Society of Plastic Surgeons (ASPS), about 768,000 total cosmetic treatments were performed in persons aged 10-29 years in 2020, and 6.1 million total cosmetic procedures were performed in people aged 40-54 years. These numbers show that surgical operations are rising in the region, which drives the need for anaesthetic medicines. The use of anaesthetics in general surgery is likely to contribute considerably to market growth. Furthermore, new anaesthetic medications are being developed in the nation, which is projected to drive market expansion. For example, in June 2020, Medova and the New York School of Regional Anesthesia (NYSORA) announced a collaboration to launch SAFIRA (SAFer Injection for Regional Anesthesia) in the United States. In addition, the Food and Drug Administration accepted a new drug application for cocaine hydrochloride (HCI; NUMBRINO) nasal solution 4% (40 mg/mL) made by Lannett Company for anaesthetic use in the United States in January 2020. Furthermore, Hikma Pharmaceuticals PLC (Hikma) introduced Bupivacaine HCl Injection USP in December 2021 via its US subsidiary Hikma Pharmaceuticals USA Inc. The business released 0.25%, 0.5%, and 0.75% in 10 millilitre and 30 millilitre dosages. Similarly, Blue-Zone Technologies Ltd got clearance from Health Canada in April 2020 for desflurane, USP, an anaesthetic medication used for general anaesthesia.